Skip to content

Robotic Minimally Invasive Ventral Hernia Repair With DEXTER

Robotic Minimally Invasive Ventral Hernia Repair With DEXTER

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07071740
Acronym
RAVEN
Enrollment
33
Registered
2025-07-17
Start date
2025-06-11
Completion date
2026-01-15
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventral Hernia Repair

Brief summary

The aim of this clinical investigation is to confirm the perioperative and early postoperative safety and clinical performance (efficacy) of the Dexter Robotic System, in patients undergoing incisional or primary ventral hernia repair.

Interventions

DEVICEventral hernia repair

Robotic-assisted incisional or primary ventral hernia repair with the DEXTER robotic surgery system

Sponsors

Distalmotion SA
Lead SponsorINDUSTRY
Confinis
CollaboratorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged \> 18 years * Planned to undergo incisional and primary midline ventral (M2-M4; epigastric, umbilical and infraumbilical) hernia repair smaller and equal to 8cm * Patient agrees to perform the 30-day follow-up assessment, as per standard of care

Exclusion criteria

* Any planned concomitant procedures * Active anticoagulant treatment * Recurring hernia with mesh during primary hernia repair * Need for transversal abdominal release * Patients under corticosteroids or other immunosuppressive treatment * Loss of domain type of hernia * Previous incision extending from xiphoid process to pubic bone (= Median laparotomy M1 to M5) * M2 hernia extending to M1 and/or M4 hernia extending to M5 * Ongoing intra-abdominal infection or septic state * Abdominal fistulae * History of major\* abdominal or pelvic surgery

Design outcomes

Primary

MeasureTime frameDescription
Primary safety 0utcomeup to 30 days after surgeryOccurrence of Clavien-Dindo grades III-V adverse events
Primary efficacy outcomeIntraoperativeSuccessful completion of the DEXTER-assisted procedure, i.e. free of any conversion to an open or fully laparoscopic surgical approach

Countries

Austria, France, Germany, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026